Ad is loading...
RSOOX
Price
$40.66
Change
-$0.11 (-0.27%)
Updated
Nov 15 closing price
VIVIX
Price
$68.70
Change
-$0.26 (-0.38%)
Updated
Nov 15 closing price
Ad is loading...

RSOOX vs VIVIX

Header iconRSOOX vs VIVIX Comparison
Open Charts RSOOX vs VIVIXBanner chart's image
Columbia Dividend Opportunity R
Price$40.66
Change-$0.11 (-0.27%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index I
Price$68.70
Change-$0.26 (-0.38%)
VolumeN/A
CapitalizationN/A
RSOOX vs VIVIX Comparison Chart
Loading...
View a ticker or compare two or three
VS
RSOOX vs. VIVIX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RSOOX is a Buy and VIVIX is a StrongSell.

FUNDAMENTALS
Fundamentals
VIVIX has more cash in the bank: 184B vs. RSOOX (2.21B). RSOOX (2.41) and VIVIX (2.37) have matching dividends . RSOOX was incepted earlier than VIVIX: RSOOX (16 years) vs VIVIX (26 years). RSOOX is a more actively managed with annual turnover of: 52.00 vs. VIVIX (10.00). RSOOX has a lower initial minimum investment than VIVIX: RSOOX (0) vs VIVIX (5000000). RSOOX (26.30) and VIVIX (25.54) have marching annual gain over last year. VIVIX return over 5 years is better than : 50.79 vs. RSOOX (19.68).
RSOOXVIVIXRSOOX / VIVIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence16 years26 years-
Gain YTD17.88417.922100%
Front LoadN/AN/A-
Min. Initial Investment05000000-
Min. Initial Investment IRAN/AN/A-
Net Assets2.21B184B1%
Annual Yield % from dividends2.412.37102%
Returns for 1 year26.3025.54103%
Returns for 3 years6.4721.5730%
Returns for 5 years19.6850.7939%
Returns for 10 years10.18110.509%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EXR164.561.13
+0.69%
Extra Space Storage
PALT1.83N/A
N/A
Paltalk
AOMR9.80-0.06
-0.61%
Angel Oak Mortgage REIT
DLO9.89-0.31
-3.04%
DLocal Limited
GYRE13.12-0.72
-5.20%
Gyre Therapeutics